Literature DB >> 6884975

Dacarbazine (DTIC)-induced human liver damage light and electron-microscopic findings.

H Dancygier, U Runne, U Leuschner, R Milbradt, M Classen.   

Abstract

The first electron-microscopic description of DTIC-induced human liver injury is presented. A 61-year-old man developed signs of hepatic failure during the second treatment cycle with DTIC for malignant melanoma. Light-microscopic examination revealed extensive centrilobular liver necrosis. Terminal hepatic venules did not show any signs of vasculitis or thrombosis and there was a lack of inflammatory infiltration. At the ultrastructural level intracytoplasmic, membrane-bound, organelle-free vacuoles were found in the hepatocytes. Liver cells showed bleb formation. Bile canaliculi were dilated and their microvilli flattened. In the pericanalicular exoplasm electron-dense fibrillary material, thought to be of microfilamentous origin, accumulated. The patient received 250 mg methylprednisolone i.v. at the very onset of symptoms and was discharged 12 days after the peak rise of transaminases with normal liver parameters.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6884975

Source DB:  PubMed          Journal:  Hepatogastroenterology        ISSN: 0172-6390


  7 in total

Review 1.  Clinical management of cytotoxic drug overdose.

Authors:  L L Thomas; M J Mertens; A E von dem Borne; C J van Boxtel; C H Veenhof; E P Veies
Journal:  Med Toxicol Adverse Drug Exp       Date:  1988 Jul-Aug

Review 2.  How recent advances in immunotherapy are changing the standard of care for patients with metastatic melanoma.

Authors:  J Wolchok
Journal:  Ann Oncol       Date:  2012-09       Impact factor: 32.976

3.  Protein thiol oxidation in murine airway epithelial cells in response to naphthalene or diethyl maleate.

Authors:  Page C Spiess; Dexter Morin; Chase R Williams; Alan R Buckpitt
Journal:  Am J Respir Cell Mol Biol       Date:  2009-10-20       Impact factor: 6.914

4.  Mechanisms of hepatotoxicity caused by dacarbazine in rats.

Authors:  R Paschke; M Heine; S Braun; K H Usadel
Journal:  J Cancer Res Clin Oncol       Date:  1993       Impact factor: 4.553

5.  Phase II study of the immune-checkpoint inhibitor ipilimumab plus dacarbazine in Japanese patients with previously untreated, unresectable or metastatic melanoma.

Authors:  N Yamazaki; H Uhara; S Fukushima; H Uchi; N Shibagaki; Y Kiyohara; A Tsutsumida; K Namikawa; R Okuyama; Y Otsuka; T Tokudome
Journal:  Cancer Chemother Pharmacol       Date:  2015-09-25       Impact factor: 3.333

Review 6.  Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma.

Authors:  Jedd D Wolchok; F Stephen Hodi; Jeffrey S Weber; James P Allison; Walter J Urba; Caroline Robert; Steven J O'Day; Axel Hoos; Rachel Humphrey; David M Berman; Nils Lonberg; Alan J Korman
Journal:  Ann N Y Acad Sci       Date:  2013-06-17       Impact factor: 5.691

Review 7.  Current status and perspectives in immunotherapy for metastatic melanoma.

Authors:  Riccardo Marconcini; Francesco Spagnolo; Luigia Stefania Stucci; Simone Ribero; Elena Marra; Francesco De Rosa; Virginia Picasso; Lorenza Di Guardo; Carolina Cimminiello; Stefano Cavalieri; Laura Orgiano; Enrica Tanda; Laura Spano; Alfredo Falcone; Paola Queirolo
Journal:  Oncotarget       Date:  2018-01-03
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.